Flash Note: Annual Financial Results 2024
(Unaudited Financial Data)
Significant Sales and EBITDA Growth – Strong increase in net profit
Paiania, 19 March 2025 – Lavipharm S.A. informs the investment community on the key financial figures for the fiscal year 2024, as well as the Group’s operational developments to date:
Consolidated Sales from ongoing operations, before Rebate & Clawback, amounted to EUR 61.01 million in 2024 compared to EUR 54.34 million during fiscal year 2023, for a 12.3% increase…